| Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group I Puzanov, A Diab, K Abdallah, CO Bingham, C Brogdon, R Dadu, ... Journal for immunotherapy of cancer 5, 1-28, 2017 | 1690 | 2017 |
| Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies J Naidoo, DB Page, BT Li, LC Connell, K Schindler, ME Lacouture, ... Annals of Oncology 26 (12), 2375-2391, 2015 | 1532 | 2015 |
| Mechanisms of cutaneous toxicities to EGFR inhibitors ME Lacouture Nature Reviews Cancer 6 (10), 803-812, 2006 | 892 | 2006 |
| Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin … ME Lacouture, EP Mitchell, B Piperdi, MV Pillai, H Shearer, N Iannotti, ... Journal of Clinical Oncology 28 (8), 1351-1357, 2010 | 531 | 2010 |
| Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities ME Lacouture, MJ Anadkat, RJ Bensadoun, J Bryce, A Chan, JB Epstein, ... Supportive Care in Cancer 19, 1079-1095, 2011 | 504 | 2011 |
| Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology JA Thompson, BJ Schneider, J Brahmer, S Andrews, P Armand, S Bhatia, ... Journal of the National Comprehensive Cancer Network 17 (3), 255-289, 2019 | 490 | 2019 |
| Epidermal growth factor receptor inhibitor–associated cutaneous toxicities: an evolving paradigm in clinical management TJ Lynch Jr, ES Kim, B Eaby, J Garey, DP West, ME Lacouture The oncologist 12 (5), 610-621, 2007 | 476 | 2007 |
| Diverse and targetable kinase alterations drive histiocytic neoplasms EL Diamond, BH Durham, J Haroche, Z Yao, J Ma, SA Parikh, Z Wang, ... Cancer discovery 6 (2), 154-165, 2016 | 445 | 2016 |
| Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor VR Belum, B Benhuri, MA Postow, MD Hellmann, AM Lesokhin, NH Segal, ... European journal of cancer 60, 12-25, 2016 | 433 | 2016 |
| Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events JR Brahmer, H Abu-Sbeih, PA Ascierto, J Brufsky, LC Cappelli, ... Journal for immunotherapy of cancer 9 (6), 2021 | 415 | 2021 |
| Evolving strategies for the management of hand–foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib ME Lacouture, S Wu, C Robert, MB Atkins, HH Kong, J Guitart, C Garbe, ... The oncologist 13 (9), 1001-1011, 2008 | 413 | 2008 |
| Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0 AP Chen, A Setser, MJ Anadkat, J Cotliar, EA Olsen, BC Garden, ... Journal of the American Academy of Dermatology 67 (5), 1025-1039, 2012 | 366 | 2012 |
| First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study RJ Sullivan, JR Infante, F Janku, DJL Wong, JA Sosman, V Keedy, ... Cancer discovery 8 (2), 184-195, 2018 | 364 | 2018 |
| Vemurafenib for BRAF V600–mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study EL Diamond, V Subbiah, AC Lockhart, JY Blay, I Puzanov, I Chau, ... JAMA oncology 4 (3), 384-388, 2018 | 360 | 2018 |
| Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia E Tiacci, JH Park, L De Carolis, SS Chung, A Broccoli, S Scott, F Zaja, ... New England Journal of Medicine 373 (18), 1733-1747, 2015 | 349 | 2015 |
| Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients R Yaeger, A Cercek, EM O'Reilly, DL Reidy, N Kemeny, T Wolinsky, ... Clinical cancer research 21 (6), 1313-1320, 2015 | 292 | 2015 |
| Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC FC Santini, H Rizvi, AJ Plodkowski, A Ni, ME Lacouture, ... Cancer immunology research 6 (9), 1093-1099, 2018 | 290 | 2018 |
| Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails M Lacouture, V Sibaud American journal of clinical dermatology 19 (Suppl 1), 31-39, 2018 | 284 | 2018 |
| Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib ME Lacouture, LM Reilly, P Gerami, J Guitart Annals of Oncology 19 (11), 1955-1961, 2008 | 284 | 2008 |
| Immune checkpoint inhibitor–related dermatologic adverse events AN Geisler, GS Phillips, DM Barrios, J Wu, DYM Leung, AP Moy, JA Kern, ... Journal of the American Academy of Dermatology 83 (5), 1255-1268, 2020 | 281 | 2020 |
